Publications and Patents

Publications

Sadik, A., L. F. Somarribas Patterson, S. Ozturk, S. R. Mohapatra, … S. Trump, M. Seiffert, and C. A. Opitz. (2020). IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 182: 1252-70 e34.

Opitz, CA., … S. Trump, …. Platten M. (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478, pages 197–203

Patents

Opitz, C. A., A. Sadik, L. F. Somarribas Patterson, S. R. Mohapatra, S. Trump, E. Faessler, and S. Schauble. (2020) WO2020201825 – Aryl hydrocarbon receptor (AHR) activation signature and methods for determining AHR signaling status.

Opitz, C. A., A. Sadik, L. F. Somarribas Patterson, S. R. Mohapatra, P. F. Secker, M. T. Prentzell and S. Trump. (2020) WO2020208190 – Interleukin-4–Induced Gene 1 (IL4I1) as a biomarker and uses thereof.

Opitz, C. A., A. Sadik, L. F. Somarribas Patterson, S. Trump and A. Bohme. (2020) PCT/EP2020/085647 – Interleukin-4-Induced Gene 1 (IL4I1) and respective metabolites as biomarkers for cancer.